I got my DNA, both in real life and in my rotisserie league draft this morning. As promised, we held our draft as soon as
was priced, and using last night's closing prices,
Melissa "Genome" Kasper
and I have now put a million mythical dollars to work in the group. Kasper went for pure speculation, I went for tried-and-true.
Why did we draft now? When we first came up with this idea of a biotech rotisserie league, the group was smoking. It rallied 50% from when we started doing our work. Although the rotisserie is meant as a way to learn, many people bought the stocks we drafted in our now famous
B2B league right after we drafted it. They then proceeded to rally hugely.
We feared that people would buy the biotech stocks similarly, as it would seem like
endorsed them at that moment, and we feared and predicted a slaughter in the group. So we waited. Fortunate we did. This group was crushed mercilessly.
We did not want to buy the first bounce. That often fails. We think that the pricing of Genentech this morning, 17 million shares, however, will mark a bottom in this group as many stocks in this cohort traded down as people sold other biotechs to get into DNA, which is a high-quality pharmaceutical company. That was our cue to get back in, hence our draft.
We are buying some of these stocks today. (Our disclosure is included at the end of the piece as always.) Frankly, I would feel much better playing this group at home with a biotech fund.
coverage of the funds that traffic in this group, especially the excellent
debate, may be the best way to start your at-home game with real money.
Remember, there were 30 names up for drafting. I wouldn't read too much into the ones that weren't drafted with the exception of the much-hyped
. I think
wins that court battle, as we own the stock at Cramer Berkowitz, and I didn't want Transkaryotic and Melissa probably didn't want to question my judgment by drafting that lawsuit play. I want to thank Melissa for writing up little bios of each stock, which can be found by clicking on our boards link.
- Abgenix (ABGX)
- Affymetrix (AFFX)
- Alexion (ALXN) - Get Report
- Amgen (AMGN) - Get Report
- Genentech (DNA)
- Human Genome Sciences (HGSI)
- Medarex (MEDX)
- MedImmune (MEDI)
- Millennium Pharmaceutical (MLNM)
- Vertex (VRTX) - Get Report
- Alkermes (ALKS) - Get Report
- Aviron (AVIR)
- Biogen (BGEN)
- Celera Genomics (CRA)
- Genzyme (GENZ)
- IDEC Pharmaceuticals (IDPH)
- Imclone Systems (IMCL)
- Immunex (IMNX)
- Inhale Therapeutic Systems (INHL)
- Lynx Therapeutics (LYNX)
Great call by
on our TV show a few weeks ago, saying that
in market cap. Boom, it did. His
piece contrasting the two this morning is the type of journalism you only get at
. ... I like
today particularly because it is using
, which seems to know what it is doing, to work out its dot-com. But, I have to tell you my wife hates its site because she says the best things about Nordstrom is the human customer service aspect, and you can only get that at the store. ...
Matt "Palm UP" Jacobs
is getting nervous after the 12-point run he just caught in
and is waffling about bailing now that the ramp has been made. Not sure what to do just yet.
James J. Cramer is manager of a hedge fund and co-founder of TheStreet.com. At time of publication, his fund was long Genentech, Amgen, Cisco Systems, Microsoft, and Palm. Cramer's fund also may be long or short certain stocks in his biotech or B2B rotisserie leagues or TheStreet.com New Tech 30 index. His fund often buys and sells securities that are the subject of his columns, both before and after the columns are published, and the positions that his fund takes may change at any time. Under no circumstances does the information in this column represent a recommendation to buy or sell stocks. Cramer's writings provide insights into the dynamics of money management and are not a solicitation for transactions. While he cannot provide investment advice or recommendations, he invites you to comment on his column at